Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606784 · ClinicalTrials.gov registry record · Phase 1
Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress
A Phase 1 study, sponsored by Ampio Pharmaceuticals..
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04606784 is a Phase 1 study that has completed, run by Ampio Pharmaceuticals.. The registered enrollment target is 40 participants.
The verdict
NCT04606784, a Phase 1 study, has completed, sponsored by Ampio Pharmaceuticals..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of nebulized Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who have respiratory distress.
Interventions
- OTHER Standard of Care
- BIOLOGICAL Ampion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04606784
The ClinicalTrials.gov registry entry for NCT04606784 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ampio Pharmaceuticals., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04606784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04606784 about?
NCT04606784 is a clinical study titled "Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress". This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of nebulized Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19 infection who have respiratory distress.
What is the current status of trial NCT04606784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-10-28. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT04606784?
The interventions under investigation include: Standard of Care (OTHER), Ampion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04606784?
This trial is sponsored by Ampio Pharmaceuticals., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.